Seeking Alpha

Dyax does first patient in DX-2930 HAE trial

  • Dyax (DYAX) says the first subject has been dosed in a Phase 1 trial for subQ DX-2930, the company's fully human monoclonal antibody inhibitor of plasma kallikrein. (PR)
  • SubQ DX-2930 is being developed for the prevention of HAE attacks.
  • Other notable HAE drugs: BCRX's BCX-4161 and VPHM's Cinryze
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: